Stockscreener 앱 받기
4.81
3.22%
-0.16
전일 마감가:
$4.97
열려 있는:
$4.97
하루 거래량:
83,534
Relative Volume:
0.53
시가총액:
$143.11M
수익:
-
순이익/손실:
$-13.08M
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.95%
1개월 성능:
+8.09%
6개월 성능:
+26.25%
1년 성능:
+0.00%
1일 변동 폭
$4.68
$5.16
1주일 범위
$4.52
$5.34
52주 변동 폭
$3.11
$20.72
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
명칭
Telomir Pharmaceuticals Inc
전화
786-396-6723
주소
100 SE 2ND ST, MIAMI
TELO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
4.81 | 143.11M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
Telomir Pharmaceuticals Confirms Copper-Binding Capabilities of Telomir-1 and Expands Pipeline into Wilson’s Disease - Defense World
Telomir Pharmaceuticals Expands Pipeline, Confirms Copper-Binding Potential of Telomir-1 for Wilson’s Disease - ChemAnalyst
Telomir-1 shows promise in copper binding studies - Investing.com
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease - AccessWire
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease - Yahoo Finance
Telomir Pharmaceuticals appoints new accounting firm - Investing.com India
Telomir Pharmaceuticals Raises $1 Million in Premium-Priced Stock Deal, Boosting Age-Reversal Research - Citybuzz
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation - Nasdaq
Telomir Pharmaceuticals enters into stock purchase agreement - MSN
Telomir Pharmaceuticals secures $1 million equity funding - Investing.com
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price - AccessWire
Telomir Pharmaceuticals Secures Premium-Priced Funding After Breakthrough Anti-Aging Drug Results - StockTitan
Telomir Pharmaceuticals secures $1 million in equity funding By Investing.com - Investing.com Canada
Telomir Pharmaceuticals secures $1 million in equity funding - Investing.com
(TELO) Technical Data - Stock Traders Daily
Stocks In Play: Renegade Gold Inc. - Barchart
Telomir-1 shows promise in diabetes preclinical study By Investing.com - Investing.com Nigeria
Unifor And PPWC Target Kruger, Inc. To Begin Western Pattern Bargaining - Barchart
Stocks In Play: Yukon Metals Corp - Barchart
Telomir-1 shows promise in diabetes preclinical study - Investing.com India
Deadline To Apply For A Special Ballot Approaches - Barchart
Media AdvisoryDeputy Prime Minister's Itinerary For Wednesday, December 4, 2024 - Barchart
AME ANNOUNCES 2024 AWARD RECIPIENTS - Barchart
Perimeter Provides Update on Canada Postal Strike and Mailing of the Company's 2024 Annual General Meeting Materials - Barchart
Ontario Lottery And Gaming CorporationMidDay Lottery Winning NumbersDec. 3, 2024 - Barchart
Stocks In Play: PyroGenesis Inc. - Barchart
Fuchs Endothelial Corneal Dystrophy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | ProQR Therapeutics, Kowa Pharmac, Trefoil Therapeutics, Alcon Inc., Emmecell - Barchart
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Preclinical Study - newsbreak.com
Telomir Pharmaceuticals' Shares Rally After Positive Results for Diabetes Treatment - MarketWatch
Gastroesophageal Adenocarcinoma Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., Merck, Taiho Pharma - Barchart
Telomir Pharmaceuticals Achieves Breakthrough in Type 2 Diabetes Treatment with Novel Age-Reversal Drug - Barchart
Enbridge Inc. Announced 3% Quarterly Dividend Increase For 2025 - Barchart
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1 - AccessWire
Telomir Pharmaceuticals reports breakthrough in diabetes study - Investing.com
Telomir Pharmaceuticals reports breakthrough in diabetes study By Investing.com - Investing.com Canada
Stocks In Play: Southern Energy Corp. - Barchart
Telomir Pharmaceuticals Inc (TELO) Recovers 37.62% From Low: Are We There Yet? - Stocks Register
Telomir Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Eton PharmaSmall Cap That's Climbing - Barchart
What is Zacks Small Cap's Estimate for TELO FY2024 Earnings? - MarketBeat
What is Zacks Small Cap’s Forecast for TELO FY2024 Earnings? - Defense World
Telomir Pharmaceuticals Insiders Still US$135k Away From Original Investment Value - Simply Wall St
NOTICE TO DISREGARD -- Wrap Technologies, Inc. - Barchart
Migraine Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Amgen, Teva Pharma, Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories - Barchart
Clarification: Crypto Lawsuit NY Story - Barchart
Launch Of The Neha Review Panel Written Dialogue - Barchart
Telomir reports findings with Telomir-1 in aging model - BioWorld Online
Filo Drills 1,270m At 0.92% CuEq In Aurora And 529m At 0.97% CuEq In Bonita - Barchart
TSX Venture Exchange Stock Maintenance Bulletins - Barchart
Three Reasons To Avoid ZVIA And One Stock To Buy Instead - Barchart
Telomir Pharmaceuticals' Breakthrough Study Reveals Major Age-Reversal Results In Advanced Preclinical Testing - Barchart
Telomir Pharmaceuticals Inc (TELO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
1.47%
자본화:
|
볼륨(24시간):